HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor

BACKGROUND: To develop peptide-based immunotherapy for osteosarcoma, we previously identified papillomavirus binding factor (PBF) as a CTL-defined osteosarcoma antigen in the context of HLA-B55. However, clinical application of PBF-based immunotherapy requires identification of naturally presented C...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukahara, Tomohide, Kawaguchi, Satoshi, Torigoe, Toshihiko, Takahashi, Akari, Murase, Masaki, Kano, Masanobu, Wada, Takuro, Kaya, Mitsunori, Nagoya, Satoshi, Yamashita, Toshihiko, Sato, Noriyuki
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702281/
https://www.ncbi.nlm.nih.gov/pubmed/19523231
http://dx.doi.org/10.1186/1479-5876-7-44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702281/
https://www.ncbi.nlm.nih.gov/pubmed/19523231
http://dx.doi.org/10.1186/1479-5876-7-44

Ejemplares similares